Silver Book Fact

Drug-resistant MRSA expensive to treat

As an example, the median treatment cost for drug-resistant MRSA patients over a 6-month period was 118% higher than the cost of treating drug-susceptible MRSA strains.

Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso. Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria. Antimicrob Agents Chemother. 2009; 54(1): 109-15. http://aac.asm.org/content/54/1/109.full

Reference

Title
Attributable Hospital Cost and Length of Stay Associated with Health Care-Associated Infections Caused by Antibiotic Resistant Gram-Negative Bacteria
Publication
Antimicrob Agents Chemother
Publication Date
2009
Authors
Mauldin, Patrick D., Cassandra D. Salgado, Ida Solhoj Hansen, Darshana T. Durup, and John A. Bosso
Volume & Issue
Volume 54, Issue 1
Pages
109-15
URL
Read Full Resource

Categories

  • Cost of Disease
  • Economic Burden

Related Facts

  • Significant increase of penicillin-resistant Streptococcus penumoniae
    High-level penicillin-resistant Steptococcus pneumoniae increased 1,000-fold over 17 years.  
  • 75% of c. diff infections start in places like nursing homes and physician offices
    75% of clostridium difficile (C. difficile) infections, a common HAI, start in places like nursing homes and physician offices.  
  • 1 in 10 HAI hospital stays from sepsis
    1 in 10 hospital stays with HAIs have a principal diagnosis of septicemia.  
  • 1 in 4 inpatient pneumonia hospitalizations due to HAIs
    In one study, one in four inpatient pneumonia hospitalizations were from health-care-associated pneumonia.  
  • Late Mortality and Sepsis
    Compared with patients not in the hospital, sepsis in hospitalized patients was associated with a 22.1%  increase in late mortality during a 2 year follow-up period.